IP Group: A £27m Pfizer Royalty Re-Rating Inside a 40% Discount
Half-year NAV ticked up to £1.14 and cash realisations beat all of 2025 — but the bull case now leans hard on one obesity royalty while a failed approach sharpens the capital-returns debate.
IPO.L · Earnings Call · 2026-09-15
A royalty re-rating, not a portfolio story
IP Group's half-year looks, on the surface, like a quiet 'steadier NAV' update: net asset value per share up about 3% to £1.14. But scratch the surface and one asset is doing a lot of the work. The company's royalty interest in Pfizer's obesity franchise was marked up by £27m in the period, to just over £150m, as the lead asset berobenatide continued through phase III and the amylin combination advanced. Greg Smith framed it plainly: “The largest fair value driver in the period was the further de-risking of Pfizer's obesity programs.” — Greg Smith, CEO · 2026-09-15 CFO David Baynes gave the mechanical explanation for that uplift — it is a probability-weighting change, not a milestone cheque: “That moved into a phase IIb trial. So that was 25% probability when we last reported. It is now 39%.” — David Baynes, CFO · 2026-09-15 This is the freshest thing in the quarter, and the company's own keyword set shows it: alongside the boilerplate, entries like combination therapy and lead program have surfaced, with the momentum entirely on the clinical side. The telling detail is Baynes' note that three programs (a GIPR alternative, a prodrug, and an earlier oral) still carry effectively zero value — so future clinical progress could add value that today's carrying figure simply does not reflect.Cash is the counterweight
If the royalty is the paper value, cash is the proof. IP Group realised £69m in the half — more than the whole of FY2025 — taking it to roughly £86m year-to-date, and £154m since the start of 2025. The cash realizations theme is not new for this company, but the pace is. Hinge Health (a 50x on invested capital), Monolith's sale to CoreWeave, and Centessa's roughly $6bn acquisition by Eli Lilly all fed the number.Management kept the £250m exit target by end-2027 front and centre, and Baynes argued visibility is better than it looks. This is future value being converted — the recurring refrain of the franchise.We generated GBP 69 million of cash proceeds in the six months, which was slightly more actually than the whole of full year 2025. A further GBP 17 million since June takes our year-to-date proceeds to the mid-GBP 80 millions.
Riding a wave the tape has cooled on
The genuinely interesting contrast is in AI. IP Group spent a chunk of the call sketching three physics-led holdings targeting AI-compute bottlenecks: Lumai (optical compute), Intrinsic (ReRAM memory), and Quantum Dice. Smith's framing: “the constraints are increasingly physical in nature — things like electricity available to data centers, the heat being produced by conventional processes, and the energy and time required to move data between the memory bit and the compute bit.” — Greg Smith, CEO · 2026-09-15That is textbook AI-infrastructure narrative, and this is where the market disagrees. The global AI data center theme is one of the biggest decliners on the 30-day tape, with the underlying semiconductor and power names sliding after a strong run. IP Group's exposure is private and small (a couple of pence per share), so it is not caught in that tape — a useful reminder that its AI story is early-stage optionality rather than a traded proxy. The data centers demand it cites and the hardware tape that prices it are, for now, moving in opposite directions. Note also the clean tech and deep-tech convergence Smith flagged — Oxa's autonomy JV with Dubai's Future Foundation, Hysata's first commercial electrolyser order — a genuinely cross-disciplinary pipeline rather than a single-sector bet.The bid that wasn't, and the discount that is
The unmissable event is governance. A 'possible offer' process over the summer (Railpen) ended without a deal, Saba holds roughly 12%, and a new chairman (Michael Queen, ex-3i) bought stock within a week of the offer period closing. Against a persistent ~40% NAV discount, the Q&A was dominated by buyback and capital allocation policy questions, with around £50m of proceeds earmarked for future returns. Smith's answer on the discount is the honest core of the whole call:Smith explicitly acknowledged the range of views from shareholders during the offer period, and the third-party capital build-out (the Climate Catalyst Fund and the Aberdeen defined-contribution mandate, managing ~£550m) is the structural lever he is pulling to reduce overhead drag.There isn't a single action that closes a discount of this size. Sustained delivery, thoughtful shareholder-focused capital allocation, continued realizations — that seems to me the most credible route to narrowing it over time.